Drugs / flt3 ligand
flt3 ligand
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02955550 | Jan 2017 → Jul 2018 | plasma cell myeloma | Celularity Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02781467 | Jul 2016 → Dec 2017 | acute myeloid leukemia | Celularity Incorporated | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00003431 | Jun 1998 → May 2001 | colorectal cancer, metastatic malignant neoplasm | Duke University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00019396 | Feb 1998 → Mar 2007 | melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00006223 | Jul 2000 → Jan 2007 | leukemia | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00020540 Background | Mar 2001 → ? | cutaneous melanoma, kidney cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005787 Background | Sep 1999 → Jan 2002 | lymphoma, neutropenia | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00006225 Background | Nov 1999 → Jan 2004 | breast cancer, leukemia, myelodysplastic/myeloproliferative disease, plasma cell neoplasm | Northwestern University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-12-09 | Celularity Incorporated | Results Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting celularity.com ↗
Results from a Phase 1 clinical study evaluating PNK-007 in patients with multiple myeloma demonstrated a single infusion of PNK-007 was well tolerated after autologous stem cell transplant (ASCT) for up to one year. |
| 2019-03-29 | Celularity Incorporated | Results Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019 celularity.com ↗
today announced results from two Phase 1 studies of PNK-007, an investigational allogeneic off-the-shelf natural killer (NK) cell therapy, in patients with acute myeloid leukemia (AML) and in patients with multiple myeloma (MM). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-12-09 | Celularity Incorporated | Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting celularity.com ↗ |
| 2019-03-29 | Celularity Incorporated | Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019 celularity.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | flt3 ligand | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006223 ↗ |
| Known as | Flt3L | “Patients receive Flt3 ligand (Flt3L) subcutaneously (SQ) alone on days 1-14.” NCT00019396 ↗ |
| Known as | PNK-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02955550 ↗ |
| Modality | Protein / enzyme biologic | “recombinant flt3 ligand” NCT00003431 ↗ |
| Route | Subcutaneous | “Patients receive flt3 ligand subcutaneously for 14 days” NCT00003431 ↗ |